research use only
Cat.No.S3758
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Inhibitors | Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tranilast Tempol Sinomenine GI254023X (GI4023) ATP Geniposidic acid CORM-3 |
|
In vitro |
DMSO
: 73 mg/mL
(199.53 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 365.85 | Formula | C19H23NO4.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 6080-33-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Cucoline hydrochloride, Kukoline hydrochloride, Sabianine A hydrochloride | Smiles | CN1CCC23CC(=O)C(=CC2C1CC4=C3C(=C(C=C4)OC)O)OC.Cl | ||
| In vitro |
Sinomenine induces apoptotic death in U87 cells via activation of caspase-3, caspase-8 and caspase-9, and down-regulation of HIAP, Bcl-2 and survivin. Sinomenine decreases the expression of phosphorylated STAT3 (p-STAT3) both in vivo and in vitro. It has beneficial roles against several types of cancers, including breast cancer cells, esophageal carcinoma cells, hepatocellular carcinoma cells, gastric adenocarcinoma cells, lung cancer cells and colon carcinoma cells. Sinomenine treatment results in dose- and time-dependent growth inhibition in U87, and IC50 of SM ranged from 178 μM to 380 μM. Treatment of U251, U373, Hs683 and T98G with Sinomenine for 48 h obviously decreases cells viability, and IC50 are 342.7 μM, 430.2 μM, 189.6 μM and 270.3 μM, respectively. Sinomenine HCl (SH) activates an autophagy-mediated cell death pathway, as indicated by the accumulated microtubule-associated protein light chain 3B (LC3B)-II, triggers autophagic flux and enhances cell viability after pretreatment with autophagy inhibitors. It induces autophagy by inhibiting the Akt-mTOR pathway and activating the JNK pathway. Sinomenine HCl (SH) dose-dependently reduces the phosphorylation of p70S6K, 4E-BP1, Akt and mTOR, while enhancing the expression levels of autophagy marker proteins in vivo and in vitro. Sinomenine HCl dose-dependently augmentes ROS generation, which is accompanied by increased autophagy in both U87 and SF767 cells. SH may promote lysosomal biogenesis by triggering the nuclear translocation of TFEB via mTOR inhibition.
|
|---|---|
| In vivo |
Sinomenine has cardioprotective, anti-inflammatory activities and cancer chemopreventive property. It exhibits anti-glioma activity in vivo. Sinomenine is well tolerated by the recipient mice at therapeutic dose, and no significant cytotoxicity is accompanied. Sinomenine HCl (SH) initiates the autophagy-lysosome pathway in both in vitro and in vivo experiments.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.